SLC5A2 and type 2 diabetes mellitus: Ertugliflozin is a selective SGLT2 inhibitor approved for use in adults with type 2 diabetes mellitus as a glucose-lowering agent [17, 18], and is being evaluated in the ongoing cardiovascular outcome trial eValuation of ERTugliflozin effIcacy and Safety (VERTIS) CV [19].